Two once-weekly injectable peptides have come to define the modern conversation about pharmacological weight loss: tirzepatide , an approved dual GIP/GLP-1 receptor agonist, and retatrutide , an investigational triple GcGR/GIP/GLP-1 agonist that adds glucagon-receptor activity to the same incretin backbone
Call your doctor at once if you have signs of a thyroid tumor, such as swelling or a lump in your neck, trouble swallowing, a hoarse voice, or shortness of breath
More serious effects that FDA labeling flags for this drug class include pancreatitis risk, thyroid C-cell changes (observed in animal studies), gallbladder disease, and hypoglycemia risk in patients combining GLP-1 agonists with insulin or sulfonylureas
Besides weight loss, tirzepatide offers substantial improvements in metabolic health, including better blood glucose levels, enhanced blood pressure, improved cholesterol profiles, and reduced inflammation markers
Mechanisms Under Investigation G-actin sequestration Binding of monomeric G-actin, modulating cytoskeletal dynamics and enabling rapid cell shape changes required for directed migration ILK pathway activation Integrin-linked kinase identified as a downstream mediator, linking actin binding to cell survival and pro-angiogenic signalling Cell migration promotion Facilitating keratinocyte, fibroblast, and endothelial cell directional migration in wound healing and tissue repair models Anti-inflammatory signalling Downregulation of NF-B activity and reduction of pro-inflammatory cytokine expression in tissue models Key Research Areas Cardiac Repair Research One of the most clinically translated Thymosin Beta-4 research areas
